Abstract
Objective: To explore whether the radioligand 2carboxymethoxy-3-(4-[123I] iodophenyl) tropane ([123I]CIT) and single-photon emission computed tomography (SPECT) can detect decreased striatal uptake in at-risk relatives of patients with Parkinson disease (PD). Patients and Methods: Ten PD patients, 10 at-risk first-degree relatives of PD patients, and 10 controls underwent [123I]-CIT and SPECT brain imaging. Their striatal uptake ratios were compared. Results: Age-adjusted specific to nonspecific striatal uptake ratios were lower in patients compared with controls and with relatives; however, ratios were similar in relatives and controls. Among relatives, ratios were consis-tently lower in subgroups postulated to be at higher risk for preclinical PD. Conclusion: Our findings provide preliminary support that [123I]β-CIT and SPECT may detect decreased striatal uptake in relatives of PD patients postulated to be at higher risk for PD.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 681-685 |
| Number of pages | 5 |
| Journal | Mayo Clinic Proceedings |
| Volume | 74 |
| Issue number | 7 |
| DOIs | |
| State | Published - 1999 |
| Externally published | Yes |
Bibliographical note
Funding Information:This study was supported in part by Guilford Pharmaceuticals, by grant NS33978 from the National Institute of Neurological Disorders and Stroke, and by Mayo Foundation.
Fingerprint
Dive into the research topics of 'Detection of preclinical parkinson disease in at-risk family members with use of [123I]-CIT and SPECT: An exploratory study'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS